As accurate detection of residual tumor cells has emerged as a key tool in evaluating efficacy and predicting failures after CD19-directed therapies, 5 these obstacles to flow cytometry are highly significant.
← all excerpts
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
1
—
—